Form 4: Regulus Therapeutics CEO Acquires Shares and Options in Recent Transaction

Regulus Therapeutics CEO, Joseph P. Hagan, acquired 50,000 shares and 1,350,000 stock options in a recent transaction.

Summary

• Joseph P. Hagan, CEO of Regulus Therapeutics, has reported a transaction involving the acquisition of 50,000 shares of common stock at a weighted average price of $1.0852 per share.
• The price range for the share purchase was between $1.065 and $1.0897.
• Hagan also acquired 1,350,000 stock options with an exercise price of $1.00 per share.
• The stock options vest monthly over a 48-month period starting January 1, 2025, contingent on continuous service to Regulus.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction by the CEO, which is generally viewed positively as it indicates confidence in the company. However, it's not a major event that would drastically alter sentiment.

Positives

• The CEO's purchase of shares and options could be seen as a positive sign of confidence in the company's future prospects.
• The vesting schedule of the options incentivizes the CEO's long-term commitment to the company.

Industry Context

This type of transaction is common for executives and is a standard part of compensation packages in publicly traded companies.

Comparison to Industry Standards

• Executive stock option grants and share purchases are a common practice in the biotechnology industry, similar to companies like Alnylam Pharmaceuticals (ALNY) and Ionis Pharmaceuticals (IONS).
• The vesting schedule of 48 months is also typical for executive stock options, aligning with industry standards for long-term incentives.

Stakeholder Impact

• The transaction may positively impact shareholder confidence due to the CEO's investment in the company.

Key Dates

Keywords

Regulus Therapeutics, RGLS, stock options, share purchase, insider trading, CEO, Joseph P. Hagan, equity